The COVID-19 pandemic has affected the entire planet, and within about a year and a half, has led to 174,502,686 confirmed cases of COVID-19 worldwide, with 3,770,361 deaths. Although it is now clear that SARS-CoV-2 can affect various different organs, including the lungs, brain, skin, vessels, placenta and others, less is yet known about adverse reactions from vaccines, although more and more reports are starting to emerge. Among the adverse events, we focused particularly on skin rashes. In this short report, we describe the case of a patient vaccinated with Comirnaty, who developed a purpuric rash resistant to oral steroid therapy after 2 weeks. To date, this is one of the very few cases in which skin biopsy was performed to better characterize the histopathological picture of this rash. Finally, we conduct a literature review of the cases of rashes from SARS-CoV-2 vaccines described in the literature, with the aim of laying foundations for future, larger case studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310051 | PMC |
| http://dx.doi.org/10.3390/vaccines9070760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Petechial and Purpuric Rashes During a Parvovirus B19 Outbreak: Are Skin Symptoms Differentiated?
Pediatr Infect Dis J
December 2024
Department of Pediatric Infectious Diseases, Katip Çelebi University, İzmir, Turkey.
Human parvovirus B19 typically causes erythema infectiosum, but unusual exanthems and hemorrhagic manifestations, such as purpuric-petechial rashes, have also been reported. PVB19-associated purpuric-petechial eruption (PAPPE) should be recognized as a distinct clinical feature of primary parvovirus B19 infection and considered in the differential diagnosis of patients with febrile purpura. This report aims to highlight several scenarios of B19V-associated petechial and purpuric rashes, which may present to pediatric departments during outbreaks.
View Article and Find Full Text PDFOsimertinib-Induced Toxic Epidermal Necrolysis - A Case Report.
Pril (Makedon Akad Nauk Umet Odd Med Nauki)
November 2024
Faculty of Medicine, University Clinic of Radiotherapy and Oncology, Skopje, Macedonia.
Purpose: To investigate the rare side effects of Osimertinib in a case of toxic epidermal necrosis.
Case Presentation: We report on a case of a 44-year old woman with lung adenocarcinoma harboring an EGFR-sensitizing mutation who was treated with Osimertinib as the second-line treatment. Ten days after Osimertinib initiation, a diffuse erythematous rash rapidly spread over the patient's trunk along with vesicles and purpuric macules; furthermore, she developed erythema and exfoliation on the face and trunk and severe mucositis.
From Viral Infection to Skin Affliction: Unveiling Mechanisms of Cutaneous Manifestations in COVID-19 and Post-COVID Conditions.
J Invest Dermatol
February 2025
Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada; Division of Dermatology, Women's College Hospital, Toronto, Canada. Electronic address:
COVID-19 skin manifestations are multifaceted, ranging from urticaria, morbilliform or papulovesicular rash, livedoid purpuric lesions, and to pseudochilblains (also called COVID toes). Recent insights into the mechanism of these manifestations have highlighted that morbilliform, papulovesicular, and livedoid/purpuric rashes are related to virus-induced endothelial cell damage and linked to moderate-to-severe disease, whereas pseudochilblains are related to an exaggerated IFN-1 production by plasmacytoid dendritic cells in protected individuals. In this paper, we will review the clinical and physiopathological features of cutaneous COVID-19 manifestations in relation to the direct viral cytopathic effects and dysregulated IFN-1 responses.
View Article and Find Full Text PDFHuman Metapneumovirus Associated With Acute Hemorrhagic Oedema of Infancy: A Case Report.
Cureus
November 2024
Paediatrics, NMC Specialty Hospital, Dubai, ARE.
Acute Haemorrhagic Oedema of Infancy (AHOI), also known as Acute Hemorrhagic Edema of Infancy (AHEI), is characterized by purpuric skin lesions, edema, and fever. It is classified as a form of cutaneous leukocytoclastic vasculitis. Clinically, AHOI presents with targetoid, purplish spots on the face and limbs, accompanied by the sudden onset of peripheral edema.
View Article and Find Full Text PDFUrticarial vasculitis.
Curr Opin Rheumatol
January 2025
Marmara University School of Medicine, Department of Dermatology, Istanbul, Türkiye.
Article Synopsis
- Urticarial vasculitis (UV) is a rare condition that can range from mild skin issues to serious systemic problems, and recent research focuses on its causes, diagnosis, and treatment options.
- New triggers for UV associated with SARS-CoV-2 and COVID-19 vaccines have been noted, along with a new clinical-dermoscopic method for diagnosis that reduces reliance on skin biopsies.
- Treatments such as antihistamines, corticosteroids, and rituximab show promise for success and long-lasting remission, while epidemiological studies show good survival rates but highlight certain severe health issues that can increase mortality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!